The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN

The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in the ALK kinase domain are typically refractory to crizotinib treatment, highli...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Dis Model Mech
Auteurs principaux: Guan, J., Tucker, E. R., Wan, H., Chand, D., Danielson, L. S., Ruuth, K., El Wakil, A., Witek, B., Jamin, Y., Umapathy, G., Robinson, S. P., Johnson, T. W., Smeal, T., Martinsson, T., Chesler, L., Palmer, R. H., Hallberg, B.
Format: Artigo
Langue:Inglês
Publié: The Company of Biologists Ltd 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5047689/
https://ncbi.nlm.nih.gov/pubmed/27483357
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.024448
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires